Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On November 15, 2022, Applied Therapeutics, Inc. (the "Company") received
written notification (the "Notice") from the Nasdaq Stock Market ("Nasdaq")
that, the Company's stockholders' equity as reported in its Quarterly Report on
Form 10-Q for the period ended September 30, 2022 (the "Form 10-Q") does not
satisfy the continued listing requirement under Nasdaq Listing Rule
5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed
company's stockholders' equity be at least $10.0 million (the "Stockholders'
Equity Requirement"). As reported in its Form 10-Q, the Company's stockholders'
equity as of September 30, 2022, was approximately $9.6 million.
The Notice has no immediate effect on the listing of the Company's common stock
on the Nasdaq Global Market. In accordance with Nasdaq Listing Rules, the
Company has 45 calendar days from the date of the Notice, or until December 30,
2022, to submit a plan to regain compliance with the Stockholders' Equity
Requirement. If the Company's compliance plan is accepted by Nasdaq, then Nasdaq
may, in its discretion, grant the Company up to 180 calendar days from the date
of the Notice, or until May 14, 2023, to evidence compliance.
The Company intends to consider available options to regain compliance with the
Stockholders' Equity Requirement, but no decisions about a response have been
made at this time. There can be no assurance that the Company will ultimately
regain compliance with all applicable Nasdaq listing criteria.
© Edgar Online, source Glimpses
APPLIED THERAPEUTICS, INC. 
